Literature DB >> 23203789

Multiple primary cancer survivors have poorer health status and well-being than single primary cancer survivors: a study from the population-based PROFILES registry.

Melissa S Y Thong1, Floortje Mols, Rob H A Verhoeven, Lifang Liu, Michael A Andrykowski, Jan A Roukema, Lonneke V van de Poll-Franse.   

Abstract

OBJECTIVE: The health status and psychosocial well-being of multiple primary cancer (MPC) survivors are under-researched.
METHODS: In total, 3615 survivors identified from the Eindhoven Cancer Registry between 2008 and 2009 were assessed. About one in six survivors had survived MPC (n = 556). All survivors completed questionnaires on health status (SF-36/European Organization of Research and Treatment of Cancer quality of life module), mental health (Hospital Anxiety and Depression Scale) and impact of cancer (Impact of Cancer).
RESULTS: Compared with single primary cancer survivors, MPC survivors reported significantly poorer scores on general health and higher symptom scores on diarrhoea and fatigue. Significantly more MPC survivors met the subclinical cut-off score of ≥ 8 points on the Hospital Anxiety and Depression Scale depression subscale (27% vs. 19%, p = 0.0001). MPC survivors also reported significantly greater negative impact of cancer (namely body changes and life interferences) and positive impact of health awareness on their lives. All results were adjusted for age at survey, time since last diagnosis, sex, comorbidity, body mass index and marital status. In secondary analyses, MPC survivors with different primary cancer combinations or time interval between primary cancer diagnoses had comparable health status and psychosocial well-being.
CONCLUSION: Multiple primary cancer survivors reported a poorer health status and, in general, experienced a greater negative impact of cancer on their psychosocial well-being than single primary cancer survivors.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer; health-related quality of life; multiple primary cancers; oncology; population based; symptoms

Mesh:

Year:  2012        PMID: 23203789     DOI: 10.1002/pon.3227

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  6 in total

1.  Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry.

Authors:  Melissa S Y Thong; Floortje Mols; Xin S Wang; Valery E P P Lemmens; Tineke J Smilde; Lonneke V van de Poll-Franse
Journal:  Eur J Cancer       Date:  2013-03-01       Impact factor: 9.162

2.  Cancer Patient Experience of Uncertainty While Waiting for Genome Sequencing Results.

Authors:  Nicci Bartley; Christine E Napier; Zoe Butt; Timothy E Schlub; Megan C Best; Barbara B Biesecker; Mandy L Ballinger; Phyllis Butow
Journal:  Front Psychol       Date:  2021-04-22

3.  Survival analysis of second primary malignancies after cervical cancer using a competing risk model: implications for prevention and surveillance.

Authors:  Runmei Li; Yue Zhang; Bingqing Ma; Kangming Tan; Henry S Lynn; Zhenyu Wu
Journal:  Ann Transl Med       Date:  2021-02

Review 4.  Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.

Authors:  Shuwen Ge; Bo Wang; Zihao Wang; Junjian He; Xiaoxin Ma
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

5.  Psychological Distress, Health Behaviors, and Benefit Finding in Survivors of Multiple Primary Cancers: Results From the 2010 Livestrong Survey.

Authors:  Sarah M Belcher; Carissa A Low; Donna M Posluszny; Rebekkah Schear; Raegan E Kramer; Heidi S Donovan
Journal:  Oncol Nurs Forum       Date:  2017-11-01       Impact factor: 1.803

6.  Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis.

Authors:  Huixun Jia; Qingguo Li; Jing Yuan; Xiaodong Sun; Zhenyu Wu
Journal:  Oncologist       Date:  2020-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.